XML 78 R59.htm IDEA: XBRL DOCUMENT v3.25.0.1
Collaborations and Other Arrangements - Narrative (Details) - USD ($)
1 Months Ended 12 Months Ended
Jul. 31, 2023
Jun. 30, 2023
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue     $ 45,042,700,000 $ 34,124,100,000 $ 28,541,400,000
Proceeds from sale of product rights     601,300,000 1,604,300,000 95,800,000
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Olanzapine Portfolio          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Proceeds from sale of product rights $ 1,050,000,000.00        
Consideration received     305,000,000    
Revenue recognized       1,450,000,000  
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Baqsimi          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Proceeds from sale of product rights   $ 500,000,000      
Consideration received     125,000,000    
Milestone payment received     450,000,000    
Revenue recognized       579,000,000  
Olumiant          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue     $ 957,400,000 922,600,000 830,500,000
Olumiant | Royalty Payments Received          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Collaborative arrangement, rights and obligations percent (up to)     20.00%    
Ebglyss | Milestone Payments, Sales-based          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Potential achievements     $ 1,250,000,000    
Ebglyss | Milestone Payments, Sales-based | Roche          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Potential achievements     1,030,000,000.00    
Orforglipron | Milestone Payments, Development and Regulatory | Chugai          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Potential achievements     140,000,000.0    
Orforglipron | Milestone Payments, Sales-based | Chugai          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Potential achievements     250,000,000.0    
COVID-19 Antibodies          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue     0 0 2,020,000,000.00
Jardiance          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue     3,340,900,000 $ 2,744,700,000 $ 2,066,000,000
Jardiance | One Time Payment Received          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue     $ 300,000,000